Raanana, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage, has filed a divisional patent application in Israel for its Trap & Target (NYSE:TGT) (T&T) platform technology.

Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a ...

Polyrizon (PLRZ) announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target platform ...

Absorptive mucosae are considered as potential sites for drug administration, including the mucosal linings of the nasal ... Delivery The design of the new nanoscale-based drug delivery systems ...

and the Trap and Target (T&T™) system, which is designed for effective nasal drug delivery. The C&C technology is developed as a nasal spray to protect against viruses and allergens, while T&T ...

RALEIGH, NORTH CAROLINA / ACCESS Newswire / January 21, 2025 / Belhaven Biopharma, a leader in dry powder nasal drug delivery systems, announces the launch of a new clinical study designed to ...

but it has also triggered a renaissance of formulation approaches amongst biopharma to bring new wave of drug substances and therapeutics to life. In the last 12 months alone, intranasal delivery ...

In addition, Polyrizon’s T&T platform is a novel drug delivery system designed for prolonged ... device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield ...